Based only on the facts in our directory. The right pick still depends on the job you need done.
Lower starting price
Not comparable
Not comparable: Artera does not list a price
Free plan
Tie
Neither has one
Higher rating
Artera
4.4 against 4.2
Same job?
Yes
Both are Healthcare AI tools
Side by side
Compared on
Artera
InHEART
Our rating
4.4Better
4.2
Starts at
Not listed
Not listed
Free plan
No
No
Category
Healthcare AI
Healthcare AI
Plans
See pricing
See pricing
Key features
Multimodal AI trained on digitized biopsy images paired with clinical data
FDA De Novo authorization for the ArteraAI Prostate Test
FDA clearance for ArteraAI Breast digital pathology risk stratification
Results delivered in as little as two days after sample submission
Inclusion in National Comprehensive Cancer Network (NCCN) treatment guidelines
AI segmentation of CT and MRI scans into interactive 3D heart models
24-hour turnaround from scan submission to delivered model
FDA 510(k)-cleared AI software for cardiac image segmentation
Ablation-strategy planning tools for electrophysiologists
Risk screening for heart failure, sudden cardiac death, and cardio-embolic stroke
Pros
Regulatory clearance (FDA De Novo, NCCN guideline inclusion) beyond most AI health startups
Published clinical evidence showing improved outcome prediction versus existing risk models
Adopted by a meaningful share of US prostate cancer clinicians already
FDA 510(k) clearance gives the AI segmentation regulatory credibility beyond a research tool
Founding team combines AI/cardiac-modeling and practicing-physician expertise directly
$15.2M in funding, including an $11M Series A, supports continued clinical development
Cons
Not a self-serve software product; access runs through labs, clinicians, and insurance billing
Pricing is not public and varies by payer and region
Limited to prostate and breast cancer currently, not a general oncology platform
No public pricing; adoption requires a hospital procurement and contracting process
Narrow clinical focus (cardiac ablation and risk screening) versus broader cardiology AI suites
24-hour model turnaround may not fit urgent or same-day procedural planning
Company
Artera, founded 2021
inHEART, founded 2017
Prices come from each vendor's pricing page, last checked 20260802. Check the vendor before you buy.
FAQ
Questions people ask
Is Artera better than InHEART?
In our reviews Artera scores 4.4 and InHEART scores 4.2. The better pick depends on the job. Artera: FDA-cleared multimodal AI that reads biopsy images and clinical data to guide cancer therapy decisions. InHEART: InHEART builds AI-generated 3D digital twins of the heart to plan cardiac ablation and predict cardiac risk.
Artera
InHEART
